Balancing cure and long-term risks in acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Pharmacology

Background:

• Childhood acute lymphoblastic leukemia (ALL) cure rates have significantly improved.
• Long-term survivors face adverse late effects from past and current treatments.
• Contemporary ALL therapies aim to reduce toxicity but still pose risks.

Purpose of the Study:

• To review long-term toxicities in pediatric ALL survivors.
• To discuss strategies for minimizing treatment burden without affecting cure rates.
• To highlight successful interventions like dexrazoxane and dexamethasone dosing.

Main Methods:

• Review of clinical trial data on pediatric ALL treatment regimens.
• Analysis of long-term sequelae in childhood ALL survivors.
• Evaluation of interventions to mitigate treatment-related toxicities.

Main Results:

• Past ALL treatments (1970s-1980s) led to well-documented long-term sequelae.
• Current pediatric ALL therapies carry risks of cardiac dysfunction, osteonecrosis, neurocognitive impairment, and second cancers.
• Dexrazoxane (cardioprotectant) and alternate-week dexamethasone (osteonecrosis reduction) are effective strategies.

Conclusions:

• Minimizing long-term toxicities in pediatric ALL survivors is a critical challenge.
• Successful interventions can reduce late effects without compromising high cure rates.
• Ongoing research focuses on balancing efficacy and safety in childhood ALL treatment.